TD Cowen Maintains Outperform on BioLife Solns, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Max Masucci maintains an Outperform rating on BioLife Solns (NASDAQ:BLFS) but lowers the price target from $29 to $25.

August 09, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioLife Solns' price target has been lowered from $29 to $25 by TD Cowen, though the Outperform rating is maintained.
The lowering of the price target by TD Cowen could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained Outperform rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100